Potassium-Sparing Diuretics Market Share

  • Report ID: 3292
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Potassium-Sparing Diuretics Market Share

North American Market Forecast

The market share of potassium-sparing diuretics in North America, amongst the market in all the other regions, is projected to be the largest with a share of about 39% by the end of 2036. The growth of the market can be attributed primarily to the increasing prevalence of cardiovascular diseases and the increasing demand for safe and effective medicines. The increasing acceptance of new technologies and the growing number of clinical trials for the development of new drugs and treatments as well as the growing investments in research and development activities by pharmaceutical and biotechnological companies, are also expected to aid in the growth of the market. A total of USD 83 billion was spent on R&D by the pharmaceutical industry in 2019 in the United States. Also, from 2010 to 2019, 59 novel drugs were approved for sale, a 60 percent increase over the previous decade. Companies are investing in research and development activities in order to develop newer and more effective potassium-sparing diuretics that can help those suffering from illnesses such as hypertension, congestive heart failure, and edema. Furthermore, the rising number of initiatives taken by governments and private organizations to create awareness about cardiovascular diagnostics and their treatments, are expected to fuel regional market growth.

APAC Market Statistics

The Asia Pacific potassium-sparing diuretics market is estimated to be the second largest, registering a share of about 25% by the end of 2036. The growth of the market can be attributed majorly to the increasing populace of geriatrics suffering from chronic kidney diseases as well as hypertension and other cardiovascular diseases. The study indicated that the overall self-reported prevalence of diagnosed CVDs was 30% for older adults aged 45 and above in India. Also, as per WHO, China's population is ageing at the fastest rate in the world. Chinese citizens over 60 are expected to reach 28% by 2040. As people age, they often develop hypertension and other conditions that require diuretics to manage water retention. Potassium-sparing diuretics are preferred for elderly individuals as they are gentler on the kidneys and help retain potassium levels, which are important for proper functioning of the heart and other organs. In addition, increasing health awareness and initiatives by governments to control the prevalence of diabetes and hypertension, and the growing focus on preventive healthcare are expected to contribute to the growth of the Asia Pacific potassium-sparing diuretics market in the near future.

Europe Market Forecast

Further, the potassium-sparing diuretics market in the Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2036. The growth of this market can be attributed to the rising prevalence of lifestyle diseases such as hypertension and diabetes. A growing awareness of early diagnosis and treatment options among regional populations is expected to boost demand for potassium-sparing diuretics. As people become more aware of the early signs of kidney disease, they are more likely to seek medical attention and treatment. Potassium-sparing diuretics are becoming increasingly popular as they help to reduce the risk of developing kidney disease.

Research Nester
Potassium-Sparing Diuretics Market Regional
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3292
  • Published Date: Jul 23, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of potassium-sparing diuretics is estimated at USD 111.32 Million.

The potassium-sparing diuretics market size was valued at USD 105.8 Million in 2023 and is likely to cross USD 220.19 Million by the end of 2036, registering more than 5.8% CAGR during the forecast period i.e., between 2024-2036. The growing prevalence of chronic diseases, such as hypertension and kidney diseases, and the increasing demand for better treatments are the major factors driving the market growth.

North America is expected to be the largest with a share of about 39% by 2036, propelled by increasing prevalence of cardiovascular diseases and the increasing demand for safe and effective medicines.

Pfizer Inc., Merck Sharp & Dohme Corp., Accord Healthcare, Amneal Pharmaceuticals LLC, Centaur Pharmaceuticals Pvt. Ltd., Validus Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., CMP Pharma, Boehringer Ingelheim GmbH, Bayer AG
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample